However, to the authors’ knowledge, only one large-scale liquid chromatography-tandem mass spectrometry (LC–MS/MS)-based quantitative proteomic study was recently developed to find biomarkers of trastuzumab-based therapy resistance from the serum of HER2-positive BC cases [45]. Here, ERBB2 is linked to breast cancer.